Clinical trials: Urinary Symptoms
Urinary Incontinence
Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are…
- Trial name
- NCT02072928
- Testing
- botulinum toxin Type A
- Where
- 6 sites in Belgium
- Volunteers
- 55 people
- Sponsor
- Allergan
Adult Nocturnal Enuresis, Urinary Incontinence (UI)
This Study Will Collect Clinical and Patient Reported Experience Data From Participants Requiring Urine Output Management Overnight in the Home Setting.
This post-market study will assess the performance of and user experience with the PureWick™ System in a home setting. The study will also observe safety of the study device and collect information from participants about their…
- Trial name
- PUREST (NCT06666426)
- Testing
- PureWick System, Hollister Female Urinary Pouch External Collection Device
- Where
- 15 sites in United States
- Volunteers
- 171 people
- Sponsor
- C. R. Bard
Stress Urinary Incontinence
Virtue® European Study
This study is a prospective, single arm, non-randomized, multi-center clinical study that will be conducted in Europe. It is designed to assess efficacy and safety of the Virtue® Male Sling in post-prostatectomy urinary…
- Trial name
- NCT01608789
- Testing
- Virtue® Male Sling
- Where
- 14 sites in Belgium, France and 6 more
- Volunteers
- 123 people
- Sponsor
- Coloplast A/S
Urinary Incontinence
Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.
- Trial name
- NCT00230789
- Testing
- Tolterodine ER 4 mg QD, OAB Patient Behavioral Training Material
- Where
- 51 sites in United States
- Volunteers
- 417 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder
Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder
The purpose of this study is to evaluate the change from baseline between the active and sham treatment groups in the treatment of urgency (urinary) incontinence episodes (leaks).
- Trial name
- Beacon (NCT01369485)
- Testing
- (VERV™ System)
- Where
- 14 sites in United States
- Volunteers
- 163 people
- Sponsor
- Ethicon Endo-Surgery
Nocturia
Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects
Demonstrate the safety and tolerability of desmopressin ODT during long-term treatment of subjects with nocturia due to nocturnal polyuria, for up to 1 year
- Trial name
- NCT03051009
- Testing
- Desmopressin ODT 25 μg, Desmopressin ODT 50 μg
- Where
- Japan
- Volunteers
- 503 people
- Sponsor
- Ferring Pharmaceuticals
Stress Urinary Incontinence, Intrinsic Sphincter Deficiency
Post Market Clinical Study to Evaluate a Mid-Urethral Vaginal Tape Procedure With a Pre-Pubic Delivery Approach, for the Treatment of Stress Urinary Incontinence
The pre-pubic approach of the tension free vaginal sling placement is a new approach in the treatment of SUI. The retropubic approach of the tension free vaginal sling is the standard method of device delivery; in addition a…
- Trial name
- NCT00688298
- Testing
- Prefyx PPS™ System, Advantage ™ System
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Urinary Incontinence
Effectiveness of PeeRelease - a Gel Absorbent Pad in Moderate to Severe Urinary Incontinence
The purpose of the proposed study is to test the effect of the new gel pad on the quality of life of urinary incontinent men and women and to assess to what extent the gel pad improves the quality of life of incontinence persons.
- Trial name
- NCT01066117
- Testing
- PeeRelease gel absorbent pad
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- Tisteron Ltd.
Lung Cancer, Head and Neck Cancer
First-in-human Study of S-588210 (S-488210+S-488211)
The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
- Conditions
- Lung Cancer, Head and Neck Cancer, Bladder Cancer, Esophageal Cancer
- Trial name
- NCT04316689
- Testing
- S-488210, S-488211
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Shionogi